AIP
BCYC

Almanack Investment Partners’s Bicycle Therapeutics BCYC Stock Holding History

Almanack Investment Partners’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-524
Closed -$12K – 275
2022
Q3 		$12K Buy
+524
New +$12.5K ﹤0.01% 443

Other funds holding BCYC

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $560K AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Almanack Investment Partners's BCYC Position: Q4 2022 in Review

Almanack Investment Partners sold out of Bicycle Therapeutics (BCYC) in Q4 2022, closing a stake of 524 shares — an estimated $12K sold.

Almanack Investment Partners first reported a position in BCYC in Q3 2022 and held it in 1 quarter. The position peaked at $12K in Q3 2022. 87 funds tracked by Wall St. Rank hold BCYC as of Q4 2022.

  • Almanack Investment Partners reported no remaining Bicycle Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 524 Bicycle Therapeutics shares in Q4 2022, an estimated $12K.
  • Almanack Investment Partners first reported a position in Bicycle Therapeutics in Q3 2022 and held it in 1 quarter.
  • Almanack Investment Partners's Bicycle Therapeutics position peaked at $12K in Q3 2022.
  • 87 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.